Martin Reck, MD, PhD of LungenClinic Grosshansdorf, Grosshansdorf, Germany talks about the overall health status in patients with advanced non-squamous (NSQ) non-small cell lung cancer (NSCLC) treated with nivolumab or docetaxel in the CheckMate 057 trial. Dr Reck explains that CheckMate 057 showed a significant improvement in terms of overall survival (OS) favoring nivolumab. For this analysis, they looked at additional endpoints such as quality of life and symptom control. The data shows a comparable impact on quality of life and on the symptom parameters of nivolumab compared to docetaxel but in terms of time to deterioration of performance status of the patient, the data shows an advantage for patients treated with nivolumab. Therefore, besides the objective effifacy there also apprears to be an impact on the quality of life and symptoms for patients treated with nivolumab. Recorded at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark.